• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

口服特比萘芬治疗轻度甲癣引发的严重药物疹——来自家庭医疗实践的病例报告及文献综述：“只是一片无害的小药丸？”

Severe drug eruption from oral terbinafine for mild onychomycosis-A case report from family practice and literature review: "Just an innocent little pill?".

作者信息

Watjer Roeland M, Eekhof Just Ah, Quint Koen D, Numans Mattijs E, Bonten Tobias N

机构信息

Department of Public Health and Primary Care, Leiden University Medical Center (LUMC), Leiden, The Netherlands.

Department of Dermatology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.

出版信息

SAGE Open Med Case Rep. 2024 Mar 4;12:2050313X241235823. doi: 10.1177/2050313X241235823. eCollection 2024.

DOI:10.1177/2050313X241235823
PMID:38444697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10913523/
Abstract

Onychomycosis is the most prevalent nail disease and is frequently encountered in clinical practice. Despite having multiple therapeutic options, of which systemic antifungals are the most effective, treatment is not always mandatory in all patients. Especially when considering systemic treatment, the risk of adverse reactions may outweigh the potential benefits of treatment. In this case report, we present a clinical case of a 49-year-old male patient with a blank past medical history who experienced a severe drug eruption from terbinafine prescribed for mild onychomycosis that required discontinuation of terbinafine, additional evaluation, and treatment of this adverse reaction.

摘要

甲癣是最常见的指甲疾病，在临床实践中经常遇到。尽管有多种治疗选择，其中全身用抗真菌药最为有效，但并非所有患者都必须进行治疗。特别是在考虑全身治疗时，不良反应的风险可能超过治疗的潜在益处。在本病例报告中，我们展示了一名49岁男性患者的临床病例，该患者既往病史空白，因轻度甲癣服用特比萘芬后发生严重药物疹，需要停用特比萘芬、进行进一步评估并治疗这种不良反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79a8/10913523/5bf578107070/10.1177_2050313X241235823-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79a8/10913523/ba3cce260d2d/10.1177_2050313X241235823-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79a8/10913523/2e546147c8a5/10.1177_2050313X241235823-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79a8/10913523/5bf578107070/10.1177_2050313X241235823-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79a8/10913523/ba3cce260d2d/10.1177_2050313X241235823-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79a8/10913523/2e546147c8a5/10.1177_2050313X241235823-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79a8/10913523/5bf578107070/10.1177_2050313X241235823-fig3.jpg

相似文献

1
Severe drug eruption from oral terbinafine for mild onychomycosis-A case report from family practice and literature review: "Just an innocent little pill?".口服特比萘芬治疗轻度甲癣引发的严重药物疹——来自家庭医疗实践的病例报告及文献综述：“只是一片无害的小药丸？”
SAGE Open Med Case Rep. 2024 Mar 4;12:2050313X241235823. doi: 10.1177/2050313X241235823. eCollection 2024.
2
Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events.特比萘芬诱发的苔藓样药疹：病例报告及特比萘芬相关皮肤不良事件综述
Dermatol Online J. 2020 Jul 15;26(7):13030/qt9jh9p0xp.
3
Safety of current therapies for onychomycosis.当前甲真菌病治疗方法的安全性。
Expert Opin Drug Saf. 2020 Nov;19(11):1395-1408. doi: 10.1080/14740338.2020.1829592. Epub 2020 Oct 12.
4
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.8%环吡酮甲涂剂溶液与美国用于治疗皮肤癣菌性足趾甲真菌病的新型口服抗真菌药物的药物经济学分析。
J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S81-95. doi: 10.1067/mjd.2000.109069.
5
Severe onychomycosis management with oral terbinafine in a kidney transplantation setting: Clinical follow-up by image analysis.在肾移植环境中口服特比萘芬治疗严重甲真菌病：通过图像分析的临床随访。
Mycoses. 2021 Mar;64(3):309-315. doi: 10.1111/myc.13220. Epub 2020 Dec 3.
6
A multicentre, randomised, parallel-group, double-blind, vehicle-controlled and open-label, active-controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis.一项多中心、随机、平行分组、双盲、阳性药对照、开放性、自身对照研究（对比阿莫罗芬 5%），旨在评估特比萘芬 10% 指甲油治疗甲真菌病的疗效和安全性。
Mycoses. 2022 Apr;65(4):392-401. doi: 10.1111/myc.13392. Epub 2021 Dec 6.
7
A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.一项多中心、随机、对照研究，比较阿莫罗芬搽剂与口服特比萘芬联合治疗与单用口服特比萘芬治疗累及甲母质的甲真菌病的疗效、安全性和成本效益。
Br J Dermatol. 2007 Jul;157(1):149-57. doi: 10.1111/j.1365-2133.2007.07974.x. Epub 2007 Jun 6.
8
Oral antifungal medication for toenail onychomycosis.用于治疗趾甲甲癣的口服抗真菌药物。
Cochrane Database Syst Rev. 2017 Jul 14;7(7):CD010031. doi: 10.1002/14651858.CD010031.pub2.
9
Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature.伊曲康唑和特比萘芬治疗某些引起脚趾甲真菌病的非皮肤癣菌霉菌及文献综述
J Cutan Med Surg. 2001 May-Jun;5(3):206-10. doi: 10.1007/s102270000019. Epub 2001 May 2.
10
Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients.甲癣：儿童和青少年中一种新出现的传染病。36例患者使用特比萘芬和伊曲康唑的治疗经验报告。
J Eur Acad Dermatol Venereol. 2008 Apr;22(4):470-5. doi: 10.1111/j.1468-3083.2007.02498.x. Epub 2008 Jan 10.

引用本文的文献

1
Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis.盐酸特比萘芬 10%溶液（MOB015B）局部用药的全身吸收和安全性：中重度甲真菌病患者 1 期最大使用量试验。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0068224. doi: 10.1128/aac.00682-24. Epub 2024 Aug 19.

本文引用的文献

1
Onychomycosis in Patients with Diabetes Mellitus in Africa: A Global Scoping Review, 2000-2021.非洲糖尿病患者的甲真菌病：2000-2021 年全球范围的系统评价。
Mycopathologia. 2023 Jun;188(3):173-182. doi: 10.1007/s11046-022-00660-7. Epub 2022 Sep 3.
2
Systematic Review of Antifungal-Induced Acute Liver Failure.抗真菌药物所致急性肝衰竭的系统评价
Cureus. 2021 Oct 21;13(10):e18940. doi: 10.7759/cureus.18940. eCollection 2021 Oct.
3
Clinical Evaluation of a Topical Formulation for the Management of Onychomycosis.一种用于治疗甲癣的外用制剂的临床评估
J Clin Aesthet Dermatol. 2020 Jul;13(7):53-57. Epub 2020 Jul 1.
4
Topical and device-based treatments for fungal infections of the toenails.用于治疗趾甲真菌感染的局部和基于器械的疗法。
Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD012093. doi: 10.1002/14651858.CD012093.pub2.
5
Recent advances in therapies for onychomycosis and its management.甲癣治疗及其管理的最新进展。
F1000Res. 2019 Jun 25;8. doi: 10.12688/f1000research.18646.1. eCollection 2019.
6
Ketoconazole and Liver Injury: A Five-Year Update.酮康唑与肝损伤：五年更新
Clin Pharmacol Drug Dev. 2019 Jan;8(1):6-8. doi: 10.1002/cpdd.652.
7
The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature.甲癣对生活质量的影响：现有文献的系统评价
Skin Appendage Disord. 2018 Oct;4(4):208-216. doi: 10.1159/000485632. Epub 2018 Feb 13.
8
Onychomycosis: Treatment and prevention of recurrence.甲真菌病：治疗和预防复发。
J Am Acad Dermatol. 2019 Apr;80(4):853-867. doi: 10.1016/j.jaad.2018.05.1260. Epub 2018 Jun 28.
9
Onychomycosis: Clinical overview and diagnosis.甲真菌病：临床概述与诊断。
J Am Acad Dermatol. 2019 Apr;80(4):835-851. doi: 10.1016/j.jaad.2018.03.062. Epub 2018 Jun 28.
10
Oral antifungal medication for toenail onychomycosis.用于治疗趾甲甲癣的口服抗真菌药物。
Cochrane Database Syst Rev. 2017 Jul 14;7(7):CD010031. doi: 10.1002/14651858.CD010031.pub2.